MaveriX Oncology is exploiting new insights into cancer and immune cell metabolism to advance a new generation of Conditionally Activated Small Molecule TherapeuticsTM designed to specifically co-target cancer and the tumor immune microenvironment.
Project in numbers
8 weeks: Duration from the idea to the final delivery
2 meetings: Communication with the client is essential for us. To listen to them and provide the best result
2 rounds: Two feedback rounds on the production stage